Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P1ME
|
|||
| Former ID |
DNCL003834
|
|||
| Drug Name |
MK-3222
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Hairy cell leukaemia [ICD-11: 2A82.2; ICD-10: C91.4] | Phase 3 | [1], [2] | |
| Plaque psoriasis [ICD-11: EA90.0; ICD-10: L40.0] | Phase 3 | [3] | ||
| Psoriasis vulgaris [ICD-11: EA90] | Phase 3 | [1], [2] | ||
| Company |
Merck
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8093). | |||
| REF 2 | ClinicalTrials.gov (NCT01936688) A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012). U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.